XML 29 R22.htm IDEA: XBRL DOCUMENT v3.20.1
Reportable Segments
 9 Months Ended
Apr. 30, 2020
Segment Reporting [Abstract]  
Reportable Segments Reportable Segments
In accordance with ASC Topic 280, “Segment Reporting,” (“ASC 280”), we have determined our reportable business segments based upon an assessment of product types, organizational structure, customers and internally prepared financial statements. The primary factors used by us in analyzing segment performance are net sales and income from operations.

In the first quarter of fiscal 2020 and as a result of the Hu-Friedy acquisition, we moved the financial reporting and management of our industrial biological and chemical indicator business to our Dental segment from our Life Sciences segment. Prior year segment disclosures have been recast to conform to the current year presentation.

Our reportable segments are as follows:
 
Medical: designs, develops, manufactures, sells and installs a comprehensive offering of products and services comprising a complete circle of infection prevention solutions. Our products include endoscope reprocessing and endoscopy procedure products.
 
Life Sciences: designs, develops, manufactures, sells, and installs water purification systems for medical and other bacteria controlled applications. We also provide filtration/separation and disinfectant technologies to the medical and life science markets through a worldwide distributor network. Two customers collectively accounted for approximately 43.3% and 40.9% of our Life Sciences segment net sales for the nine months ended April 30, 2020 and 2019, respectively.

Dental: designs, manufactures, sells, supplies and distributes a broad selection of infection prevention healthcare products, the majority of which are single-use products used by dental practitioners. We are also a leading global manufacturer of instruments and instrument reprocessing workflow systems serving the dental industry. Three customers collectively accounted for approximately 42.3% and 45.7% of our Dental segment net sales for the nine months ended April 30, 2020 and 2019, respectively.

Dialysis: designs, develops, manufactures, sells and services reprocessing systems and sterilants for dialyzers (a device serving as an artificial kidney), as well as dialysate concentrates and supplies utilized for renal dialysis. Three customers accounted for approximately 45.7% and 45.6% of our Dialysis segment net sales for the nine months ended April 30, 2020 and 2019, respectively. These customers include the top two customers noted above under our Life Sciences segment.

No customer accounted for 10% or more of our consolidated net sales for the nine months ended April 30, 2020 and 2019.

Information as to reportable segments is summarized below
 Three Months Ended April 30,Nine Months Ended April 30,
Net sales2020201920202019
Medical$101,222  $130,722  $365,534  $386,854  
Life Sciences48,189  44,975  147,452  147,333  
Dental79,170  45,131  247,457  120,548  
Dialysis8,352  7,724  22,234  23,944  
Total net sales$236,933  $228,552  $782,677  $678,679  

 Three Months Ended April 30,Nine Months Ended April 30,
Income from operations2020201920202019
Medical$6,153  $24,302  $48,806  $75,038  
Life Sciences5,786  4,091  20,621  16,364  
Dental1,549  5,509  5,697  17,703  
Dialysis1,859  1,151  4,988  3,728  
 15,347  35,053  80,112  112,833  
General corporate expenses(1)
(7,097) 20,241  35,648  44,147  
Total income from operations$22,444  $14,812  $44,464  $68,686  
_______________________________________________
(1)Includes fair value adjustments for contingent consideration arrangements related to the Hu-Friedy acquisition.